Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Informatics » Chugai Pharmaceutical Signs Agreement on Combinatorial Chemistry

Chugai Pharmaceutical Signs Agreement on Combinatorial Chemistry

Dec 21, 1998
Premium

INDIANAPOLIS--Earlier this month, Eli Lilly here announced a deal with Tokyo-based Chugai Pharmaceutical in which the American firm will share proprietary combinatorial chemistry expertise in exchange for up-front fees, milestone payments, and royalties on the first two products that reach the market as a result of the collaboration. Among the techniques and technologies that will be shared are some gained as a result of Lilly's 1994 acquisition of Sphinx Pharmaceuticals, which significantly expanded Lilly's competence in combinatorial chemistry.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

And Maybe Not

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Now Onto a Hungry Caterpillar

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

This Variant Here

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

Nature Papers Present Tool for Topological Analysis of Chromosomes, Map of Genome-Lipid Associations

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
01
Featured Webinar

Immune Repertoire Sequencing to Uncover SARS-CoV-2-Specific T Cell Responses and Dynamics

Sponsored by
Adaptive Biotechnologies

T cells are the adaptive immune system’s first responders to any virus, circulating in the blood to detect and quickly multiply to attack the virus, and also support the development of antibodies by B cells. 

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
26
Featured Webinar

Robust CNV Detection Using Whole-Exome Sequencing for Complex Cases

Sponsored by
Sophia Genetics

This webinar will discuss Genotypos Science Labs’ experience with a whole-exome sequencing solution supporting the detection of copy number variants (CNVs) for the management of complex cases.

What's Popular?

In Informatics

  1. Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization

  2. Google DeepVariant Boosts Accuracy of Indel Calls in PacBio Long Reads

    Premium

  3. Center for Genomic Regulation's COVID-19 Viral Beacon Digs Into Thousands of SARS-CoV-2 Genomes

    Premium

  4. Genosity Inks Comarketing Agreement with Personal Genome Diagnostics

  5. Kaiser Permanente Taps BC Platforms to Analyze Biobank, Clinical Data

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.